Is Ozempic Covered for Weight Loss? (2026)

Direct Answer: Why Ozempic Is Denied for Weight Loss

No. Ozempic is not covered for weight loss in 2026 under any major insurance type. For retail pricing, see Ozempic cost without insurance. The FDA approved Ozempic (semaglutide 0.5 mg, 1 mg, and 2 mg) for type 2 diabetes glycemic control and for cardiovascular risk reduction in adults with type 2 diabetes and established cardiovascular disease. Weight loss is a side effect, not an approved indication. Insurers pay based on FDA-approved indications; prior authorization requests with an obesity diagnosis are routinely denied.

Ozempic vs. Wegovy: Same Drug, Different FDA Indications

Ozempic and Wegovy both contain semaglutide, manufactured by Novo Nordisk, but they are separate FDA-approved drugs with different intended uses. Ozempic comes in prefilled pens of 0.5 mg, 1 mg, and 2 mg doses, approved in 2017 for type 2 diabetes. Wegovy comes in a prefilled pen delivering 2.4 mg per dose, approved in June 2021 for chronic weight management. The 2.4 mg dose of Wegovy is higher than any available Ozempic dose, reflecting that obesity management requires more intensive semaglutide exposure than glycemic control.

Insurance carriers treat these as separate formulary line items precisely because their FDA indications differ. A plan that covers Ozempic at Tier 3 for diabetes may simultaneously exclude Wegovy or place it in a specialty tier requiring prior authorization. Asking your doctor to prescribe Ozempic instead of Wegovy to avoid an obesity drug exclusion is a practice most major payers have flagged; the diagnosis code on the prior authorization determines coverage, not the drug name alone.

How Original Medicare Handles Ozempic and Wegovy in 2026

Original Medicare Part D has covered Ozempic for type 2 diabetes management since the drug launched in 2018. Medicare Part D does not cover Ozempic for weight loss because weight loss is not an FDA-approved indication for that formulation. For many years, Medicare Part D was also prohibited by statute from covering anti-obesity medications at all. That changed through two separate developments in 2024 and 2026.

First, the FDA granted Wegovy a separate approval in 2024 for cardiovascular risk reduction in adults with obesity or overweight and established cardiovascular disease, based on the SELECT trial published in 2023. That cardiovascular approval placed Wegovy in the same category as other cardiovascular drugs that Part D is already required to cover. CMS confirmed that Medicare Part D plans must cover Wegovy for enrollees who have established cardiovascular disease (prior heart attack, stroke, or peripheral arterial disease) and meet Wegovy's BMI criteria. Ozempic does not qualify for this pathway in obesity-only patients because Ozempic's cardiovascular approval requires a type 2 diabetes diagnosis.

Second, CMS launched the Medicare GLP-1 Affordability Demonstration starting July 2026. This demonstration program covers Wegovy and Zepbound (tirzepatide) for weight management in Medicare Part D enrollees regardless of cardiovascular history, with a beneficiary copay of approximately $50 per month. This is a time-limited CMS demonstration, not a permanent statutory change. Beneficiaries who qualify for the CVD coverage pathway and the demonstration may use whichever route produces lower out-of-pocket cost. A Medicare Part D enrollee with obesity alone and no cardiovascular disease had no covered path to any GLP-1 for weight loss before July 2026; the demonstration creates that path.

ACA Marketplace Plans and Employer Plans: No Mandate, Wide Variation

ACA marketplace plans are required to cover the 10 Essential Health Benefits, but obesity drugs are not among them. No ACA rule requires a marketplace plan to cover Ozempic or Wegovy for weight loss. Plans may choose to include these drugs voluntarily, and some do, but many 2026 marketplace plans exclude obesity drugs entirely or cover them only with elevated cost-sharing. Employer-sponsored plans under ERISA have even greater flexibility and are not bound by state insurance mandates on obesity drug coverage.

For Ozempic specifically, ACA marketplace plans that list it on their formulary will typically cover it only with a type 2 diabetes ICD-10 diagnosis code (E11.x). If the claim is submitted with an obesity diagnosis code (E66.x) and no diabetes code, the prior authorization will almost always be denied. Some patients and prescribers have attempted to use a diabetes prevention or insulin resistance code to secure coverage, but most major payers have closed these pathways through formulary edits requiring a confirmed T2D diagnosis.

Medicaid Coverage of Ozempic and Wegovy in 2026

Medicaid coverage of GLP-1 drugs varies significantly by state. See does Medicaid cover GLP-1 by state. Most state Medicaid programs cover Ozempic for type 2 diabetes on their formularies, typically in a preferred or non-preferred tier with prior authorization. Coverage of Wegovy for obesity is far less common. A KFF analysis from 2025 found that fewer than half of state Medicaid programs covered any obesity drug, and several that did required prior authorization, a documented BMI threshold, and failed trials of at least two other weight-loss approaches.

Medicaid programs face no federal mandate to cover obesity drugs. States that have expanded Medicaid under the ACA must cover ACA Essential Health Benefits, which do not include obesity pharmacotherapy. A Medicaid enrollee seeking Ozempic for weight loss in most states in 2026 will receive a denial. Enrollees in California (Medi-Cal), New York, and a handful of other states with explicit obesity drug coverage policies may have a path to Wegovy coverage if BMI and comorbidity criteria are met, but Ozempic off-label for weight loss remains excluded even there.

Alternatives if You Cannot Get Coverage for Weight Loss Drugs

Novo Nordisk offers a patient assistance program for Wegovy and Ozempic for people who meet income criteria and lack insurance coverage. Eligibility in 2026 generally requires income below 400% of the federal poverty level ($63,840 for an individual in 2026) and no other coverage of the drug. Applications are submitted through novonordisk-us.com or NeedyMeds.org.

Other FDA-approved weight loss medications with broader insurance coverage include phentermine-topiramate (Qsymia), naltrexone-bupropion (Contrave), and orlistat (Alli, Xenical). These older drugs have lower list prices and wider formulary placement. For Medicare Part D beneficiaries who do not qualify for the CVD coverage pathway and whose plan does not participate in the GLP-1 Bridge demonstration, these older agents may be the primary pharmacological options in 2026. Lifestyle programs through a registered dietitian and behavioral counseling for obesity are covered as preventive services under ACA plans and by Medicare Part B, and represent a coverage-guaranteed starting point for all patients.

The FDA removed compounded semaglutide from its drug shortage list in early 2025, which means compounding pharmacies generally can no longer legally compound it except for specific documented patient needs. Patients should consult their prescriber before pursuing compounded alternatives. The FDA has stated that compounded semaglutide products are not FDA-approved substitutes for Ozempic or Wegovy.

What to Do If You Have Type 2 Diabetes and Want Ozempic

Patients with a confirmed type 2 diabetes diagnosis have a legitimate path to Ozempic coverage through most insurance plans in 2026. The prior authorization process typically requires documentation of the T2D diagnosis, an A1C value showing the need for additional glycemic control, and evidence that at least one other diabetes medication (usually metformin) was tried first, if the plan uses step therapy. Your prescribing physician can assist by submitting clinical notes, lab values, and the ICD-10 code for type 2 diabetes (E11.x).

If the initial prior authorization is denied for Ozempic with a diabetes diagnosis, the denial must be given in writing with a specific reason. You have the right to appeal within the timeframe stated in the denial letter, typically 30 to 60 days. Your physician can submit a peer-to-peer review request where a treating physician speaks directly with the insurance medical reviewer. A clinical appeal letter citing the 2026 ADA Standards of Medical Care in Diabetes, which includes GLP-1 receptor agonists as a preferred class for patients with cardiovascular disease, can support the appeal.

How to Find a Plan That Covers Wegovy for Weight Loss

During ACA open enrollment (November 1 through January 15 for 2026 plan year coverage), the healthcare.gov plan comparison tool lets you search for plans that cover specific drugs. Enter Wegovy in the drug search to see which plans include it on their formulary and at what tier. Look for plans where Wegovy appears as Tier 3 or Tier 4 rather than excluded or requiring a specialty pharmacy with unlimited prior authorization.

For Medicare beneficiaries, the Medicare Plan Finder at medicare.gov/plan-compare allows the same drug-specific search across all available Part D and Medicare Advantage plans in your ZIP code. Beneficiaries with obesity and established cardiovascular disease should include Wegovy in their drug search, as plans must cover it for that indication. Beneficiaries without cardiovascular disease should check whether their Part D plan participates in the CMS GLP-1 Affordability Demonstration beginning July 2026, which covers Wegovy and Zepbound at approximately $50 per month. If a plan appears to exclude Wegovy improperly, call member services and reference your cardiovascular diagnosis or ask about the CMS demonstration program.

Does insurance cover Ozempic for weight loss if I don't have diabetes?

No. Ozempic is FDA-approved for type 2 diabetes only. Insurance plans pay based on FDA-approved indications and internal formulary rules. A prior authorization request for Ozempic with an obesity or weight loss diagnosis will be denied by virtually all plans. Wegovy (semaglutide 2.4 mg) is the FDA-approved drug for weight loss and is the correct prescription if your goal is obesity treatment rather than diabetes management.

Does Medicare cover Ozempic for weight loss in 2026?

No. Medicare Part D does not cover Ozempic for weight loss. Ozempic is covered by Part D only for type 2 diabetes management. For weight loss, Medicare has two pathways for Wegovy: (1) for enrollees with obesity plus established cardiovascular disease, Part D must cover Wegovy based on its FDA cardiovascular risk reduction approval; (2) for enrollees without cardiovascular disease, the CMS GLP-1 Affordability Demonstration starting July 2026 covers Wegovy and Zepbound at approximately $50 per month copay.

What is the difference between Ozempic and Wegovy?

Both contain semaglutide, but they have different FDA-approved indications and dose strengths. Ozempic (0.5 mg, 1 mg, 2 mg) is approved for type 2 diabetes. Wegovy (2.4 mg) is approved for chronic weight management in adults with obesity (BMI 30 or higher) or overweight (BMI 27 or higher) with at least one weight-related condition. Wegovy's separate cardiovascular approval from the SELECT trial in 2023 is what enabled Medicare Part D coverage for enrollees with established CVD.

Can I ask my doctor to prescribe Ozempic off-label for weight loss?

Your doctor can write the prescription, but your insurance almost certainly will not pay for it. Off-label prescribing is legal, but insurers cover drugs based on FDA-approved indications. Without a type 2 diabetes diagnosis, expect the pharmacy or insurer to reject the claim. The correct approach for weight loss coverage is to discuss Wegovy with your physician and work through that drug's prior authorization process.

Does Medicaid cover Wegovy for obesity?

Rarely. Most state Medicaid programs in 2026 do not cover obesity drugs, including Wegovy. There is no federal mandate for Medicaid to cover obesity pharmacotherapy. A few states (California's Medi-Cal, New York, and several others) have added limited obesity drug coverage with specific BMI and comorbidity requirements, but these are exceptions. Contact your state Medicaid office or managed care plan to check your specific state's policy.

Does ACA marketplace insurance have to cover weight loss drugs?

No. Obesity drugs are not among the 10 ACA Essential Health Benefits, so marketplace plans are not required to cover Wegovy, Ozempic, or any other GLP-1 for weight loss. Some marketplace plans choose to include obesity drugs voluntarily. During open enrollment, use the healthcare.gov plan comparison tool to search for plans that include Wegovy on their formulary before you enroll.

What is the cost of Ozempic without insurance in 2026?

The list price of Ozempic without insurance is approximately $990 per month in 2026 (manufacturer WAC). Wegovy's list price is approximately $1,350 per month. Novo Nordisk offers a patient savings card that can reduce cost to $25 per month for commercially insured patients who meet criteria, and a patient assistance program for uninsured patients below 400% FPL (approximately $63,840 for an individual in 2026).

What other weight loss drugs are covered by insurance?

FDA-approved weight loss drugs with broader insurance coverage include phentermine-topiramate (Qsymia), naltrexone-bupropion (Contrave), and orlistat (Alli, Xenical). These older agents have lower list prices and appear on more formularies. For Medicare Part D enrollees who do not qualify for the CVD coverage pathway and whose plan does not participate in the GLP-1 Bridge demonstration, these remain the primary pharmacological options with coverage in 2026. Behavioral counseling for obesity is covered as a preventive service under ACA plans and Medicare Part B.